摘要
目的:研究芳香化酶P450在子宫内膜癌中的表达,探讨其在早期诊断、治疗中的临床意义。方法:应用免疫组化SP法对子宫内膜癌50例的芳香化酶P450、雌激素受体(ER)、孕激素受体(PR)的表达进行研究,并设子宫颈原位癌30例作为对照组。结果:子宫内膜癌中P450arom阳性表达率为92%,与对照组0%有显著性差别,其阳性表达与子宫内膜癌的分期、组织分化程度、有无淋巴结转移无明显相关性。P450arom的表达与ER、PR的表达无正相关关系。结论:P450arom的异常表达与子宫内膜癌的发生有关,为促进子宫内膜恶变的因素之一,提示P450arom可为子宫内膜组织早期癌变的生物学标记之一,芳香化酶抑制剂可成为治疗子宫内膜癌的一个新途径。
Objective To investigate the expression of aromatase P450 in endometfial carcinoma and evaluate its clinical significance in the early diagnosis and treatment of the malignancy. Methods The expressions of aromatase P450, estrogen receptor （ER）, and progesterone receptor （PR） were detected using immunohistochemical S-P method in 50 patients with endometrial carcinoma. Thirty cases of cervical carcinoma in situ were used as control. Results The positive rate of aromatase P450 expression differed significantly between endometrial carcinoma and cervical carcinoma in situ （92% vs. 0%） and it was nonsignificantly associated with stage, degree of cell differentiation, and presence or absence of lymph node metastases. There was no positive correlation between aromatase P450 and ER or PR. Conclusion The aberrant expression of aromatase P450 is related to the genesis of endometfial carcinoma, suggesting that aromatase P450 may be one of the biochemical markers in the early endometrial carcinogenesis. P450 enzyme inhibitors may become a novel therapy for endometrial carcinoma.
出处
《实用医学杂志》
CAS
2008年第4期564-566,共3页
The Journal of Practical Medicine
关键词
子宫内膜肿瘤
受体
雌激素
芳香化酶P450
孕激素受体
免疫组化SP法
Endometrial neoplasms Receptor, estrogen Aromatase cytochrome P450 Progesterone receptor Immunohistochemical S-P method
